Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Thoracic 1Myeloid 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Temozolomide 147Radiotherapy 90Cyclophosphamide 53Magnetic Resonance Spectroscopy 42Radiation 41Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 26Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 18Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Practice Guidelines as Topic × CNS × Clear all
NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Mayo Clinic

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡